Growth and geographic variation in hospitalizations with resistant infections, United States, 2000-2005.
From 2000 through 2005, hospitalizations with resistant infections (methicillin-resistant Staphylococcus aureus, Clostridium difficile-associated disease, vancomycin-resistant enterococcus, Pseudomonas aeruginosa, and Candida infection) nearly doubled, from 499,702 to 947,393. Regional variations noted in the aggregate and by individual infection may help clarify modifiable risk factors driving these infections.
Zilberberg
Marya D
MD
EviMed Research Group, LLC, Goshen, Massachussetts 01032, USA. marya@evimedgroup.org
Shorr
Andrew F
AF
Kollef
Marin H
MH
D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000453:epidemiology* / Q000382:microbiology; D016360:Clostridioides difficile / Q000187:drug effects; D025141:Drug Resistance, Fungal; D016983:Enterococcus / Q000187:drug effects; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006761:Hospitals; D006801:Humans; D015994:Incidence; D017053:Infection Control; D008499:Medical Records; D008712:Methicillin / Q000008:administration & dosage; D016106:Methicillin Resistance; D011552:Pseudomonas Infections / Q000453:epidemiology* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013203:Staphylococcal Infections / Q000453:epidemiology*; D013211:Staphylococcus aureus / Q000187:drug effects; D014481:United States / Q000453:epidemiology; D014640:Vancomycin / Q000008:administration & dosage; D020713:Vancomycin Resistance
D014640:Vancomycin; D008712:Methicillin